Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2018 08:00 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives

- Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB...
April 02, 2018 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

DURHAM, NC, April 02, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
March 28, 2018 17:00 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018

DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
February 15, 2018 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
February 05, 2018 16:47 ET | Source: Argos Therapeutics, Inc.

Argos Obtains Option to License PD1 Checkpoint Inhibitors

- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on...
January 18, 2018 08:00 ET | Source: Argos Therapeutics, Inc.

Argos Announces One-for-Twenty Reverse Stock Split

DURHAM, N.C., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
January 08, 2018 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd.

DURHAM, N.C., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
November 28, 2017 08:00 ET | Source: Argos Therapeutics, Inc.

Argos Provides Financial Update

DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
November 11, 2017 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

DURHAM, N.C., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
November 09, 2017 16:46 ET | Source: Argos Therapeutics, Inc.

Argos Reports Third Quarter 2017 Financial Results and Operational Highlights

DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...